Video

Dr. Wierda on the Results of the CAPTIVATE Trial in CLL and SLL

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

William G. Wierda, MD, PhD, professor, D. B. Lane Cancer Research Distinguished Professor, section chief of Chronic Lymphocytic Leukemia, center medical director, Department of Leukemia, Division of Cancer Medicine, and executive medical director, The University of Texas MD Anderson Cancer Center, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The multicenter, double-blind, phase 2 CAPTIVATE study ​randomized patients with CLL or SLL who had confirmed rates of undetectable minimal residual disease (uMRD) to receive ibrutinib (Imbruvica) or placebo after 12 cycles of ibrutinib plus venetoclax (Venclexta). Patients who did not meet the definition of ​uMRD were randomized to ibrutinib ​or continued ibrutinib and venetoclax. The primary end point ​of the study was disease-free survival (DFS), Wierda says.

Results ​of the study, which were presented virtually during the 2020 ASH Annual Meeting, showed that the 1-year DFS ​rate in patients who ​had uMRD and received ibrutinib (100%; 95% CI, 100%-100%) was not significantly different from the 1-year DFS rate in patients who received placebo (95.3%; 95% CI​, 82.7​%-98.8​%; P = .1475). These findings support the role of fixed-duration targeted ​combination strategies in patients who achieve uMRD status, Wierda concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity